Martins Eduardo Bruno 4

What Happened

Martins Eduardo Bruno, Chief Medical Officer of Sagimet Biosciences, was granted two equity awards on February 19, 2026: 44,000 restricted stock units (RSUs) and 88,000 derivative awards (option-based rights). Both grants show an acquisition price of $0.00 — these are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: February 19, 2026; Form 4 filed February 20, 2026 (timely filing).
• Awards: 44,000 RSUs (F1) and 88,000 derivative awards/options (A, derivative). No cash paid ($0.00 per share).
• Vesting: RSUs vest in four equal annual installments beginning Feb 19, 2026 (F1). The derivative awards vest and become exercisable in 48 equal monthly installments beginning Feb 19, 2026 (F2).
• Shares owned after transaction: Not disclosed in this filing.
• No indication of a 10b5-1 plan, tax withholding sale, or late filing in this record.

Context

RSUs convert to actual shares upon vesting and settlement; the 88,000 derivative awards are option-like and will only become exercisable over time as they vest. Because these are compensation grants rather than purchases or sales, they reflect standard equity-based compensation rather than an immediate trading decision.